BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...molecules, antibodies or other targeting domains, such as the phospholipid ether (PLE) vector developed by Cellectar Biosciences Inc....
BioCentury | Dec 19, 2018
Distillery Therapeutics

Inflammation; pulmonary

...oral PI3K inhibitor, in Phase I through Phase III testing for a variety of cancers. Cellectar Biosciences Inc....
BioCentury | Jul 17, 2018
Clinical News

Cellectar's CLR 131 reduces tumor burden by 94% in patient with Waldenström's macroglobulinemia

...B cell hematologic malignancies. CLR 131 is an iodine-radiolabeled small molecule phosphoinositide 3-kinase (PI3K) inhibitor. Cellectar Biosciences Inc....
...overall survival (OS) Status: Phase II data Milestone: NA Jaime De Leon CLR 131, I-131-CLR1404 (HOT), (131)I-CLR1404 HOT Cellectar Biosciences Inc. Phosphoinositide...
BioCentury | Oct 20, 2017
Financial News

Cellectar raises $7.8M in registered direct offering

...On Oct. 12, Cellectar Biosciences Inc. (NASDAQ:CLRB) raised $7.8 million through the sale of shares and convertible stock...
...candidate is an iodine-radiolabeled small molecule phosphoinositide 3-kinase (PI3K) inhibitor. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Allison Johnson CLR 131 Cellectar Biosciences Inc....
BioCentury | Oct 13, 2017
Company News

Cellectar and Pierre Fabre extend PDC deal

...respond to inquiries. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wisc. Pierre Fabre Group , Castres, France Business: Cancer Shannon Lehnbeuter Cellectar Biosciences Inc. Pierre...
BioCentury | Aug 18, 2017
Clinical News

Cellectar reports OS of 22.5 months in Phase I MM trial of CLR 131

...inhibitor, is also in a Phase II trial to treat MM and other hematologic malignancies. Cellectar Biosciences Inc....
...Status: Additional Phase I data Milestone: Additional Phase I data (3Q17) Jaime De Leon (131)I-CLR1404 HOT CLR 131 I-131-CLR1404 (HOT) Cellectar Biosciences Inc. Phosphoinositide...
BioCentury | Apr 4, 2017
Clinical News

CLR 131: Ph II started

...myeloma (MM). Patients will have the option to receive a second dose 75-180 days later. Cellectar Biosciences Inc....
...median overall survival (OS) Status: Phase II started Milestone: Phase II data (2H17) Julian Zhu CLR 131 I-131-CLR1404 (HOT) Cellectar Biosciences Inc. Phosphoinositide...
BioCentury | Mar 17, 2017
Company News

WARF, Cellectar deal

...terms. Wisconsin Alumni Research Foundation , Madison, Wis. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Business: Cancer Chris Lieu CLR 131 Cellectar Biosciences Inc. Wisconsin...
BioCentury | Jan 6, 2017
Finance

Good riddance

...NYSE-M:PTN) (A) 12/1/16 $16.5 NA $68.0 NA Xencor Inc. (NASDAQ:XNCR) 12/1/16 $126.5 $1,113.9 $1,221.6 10% Cellectar Biosciences Inc....
BioCentury | Dec 1, 2016
Financial News

Cellectar completes follow-on

...each preferred share sold. The five-year warrants are exercisable at $1.50. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Alicia Parker Cellectar Biosciences Inc....
Items per page:
1 - 10 of 120
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

...molecules, antibodies or other targeting domains, such as the phospholipid ether (PLE) vector developed by Cellectar Biosciences Inc....
BioCentury | Dec 19, 2018
Distillery Therapeutics

Inflammation; pulmonary

...oral PI3K inhibitor, in Phase I through Phase III testing for a variety of cancers. Cellectar Biosciences Inc....
BioCentury | Jul 17, 2018
Clinical News

Cellectar's CLR 131 reduces tumor burden by 94% in patient with Waldenström's macroglobulinemia

...B cell hematologic malignancies. CLR 131 is an iodine-radiolabeled small molecule phosphoinositide 3-kinase (PI3K) inhibitor. Cellectar Biosciences Inc....
...overall survival (OS) Status: Phase II data Milestone: NA Jaime De Leon CLR 131, I-131-CLR1404 (HOT), (131)I-CLR1404 HOT Cellectar Biosciences Inc. Phosphoinositide...
BioCentury | Oct 20, 2017
Financial News

Cellectar raises $7.8M in registered direct offering

...On Oct. 12, Cellectar Biosciences Inc. (NASDAQ:CLRB) raised $7.8 million through the sale of shares and convertible stock...
...candidate is an iodine-radiolabeled small molecule phosphoinositide 3-kinase (PI3K) inhibitor. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Allison Johnson CLR 131 Cellectar Biosciences Inc....
BioCentury | Oct 13, 2017
Company News

Cellectar and Pierre Fabre extend PDC deal

...respond to inquiries. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wisc. Pierre Fabre Group , Castres, France Business: Cancer Shannon Lehnbeuter Cellectar Biosciences Inc. Pierre...
BioCentury | Aug 18, 2017
Clinical News

Cellectar reports OS of 22.5 months in Phase I MM trial of CLR 131

...inhibitor, is also in a Phase II trial to treat MM and other hematologic malignancies. Cellectar Biosciences Inc....
...Status: Additional Phase I data Milestone: Additional Phase I data (3Q17) Jaime De Leon (131)I-CLR1404 HOT CLR 131 I-131-CLR1404 (HOT) Cellectar Biosciences Inc. Phosphoinositide...
BioCentury | Apr 4, 2017
Clinical News

CLR 131: Ph II started

...myeloma (MM). Patients will have the option to receive a second dose 75-180 days later. Cellectar Biosciences Inc....
...median overall survival (OS) Status: Phase II started Milestone: Phase II data (2H17) Julian Zhu CLR 131 I-131-CLR1404 (HOT) Cellectar Biosciences Inc. Phosphoinositide...
BioCentury | Mar 17, 2017
Company News

WARF, Cellectar deal

...terms. Wisconsin Alumni Research Foundation , Madison, Wis. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Business: Cancer Chris Lieu CLR 131 Cellectar Biosciences Inc. Wisconsin...
BioCentury | Jan 6, 2017
Finance

Good riddance

...NYSE-M:PTN) (A) 12/1/16 $16.5 NA $68.0 NA Xencor Inc. (NASDAQ:XNCR) 12/1/16 $126.5 $1,113.9 $1,221.6 10% Cellectar Biosciences Inc....
BioCentury | Dec 1, 2016
Financial News

Cellectar completes follow-on

...each preferred share sold. The five-year warrants are exercisable at $1.50. Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Alicia Parker Cellectar Biosciences Inc....
Items per page:
1 - 10 of 120